Trou­bled Alzheimer's play­er Cor­texyme says good­bye to found­ing team as in­de­pen­dent in­vestor takes chair­man­ship

When Cor­texyme’s lead­er­ship got on an an­a­lyst call last Oc­to­ber to dis­cuss the re­sults for their lead Alzheimer’s drugs, many lis­ten­ers were be­wil­dered.

The tri­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER